Hydroxyvitamin D assays: An historical perspective from DEQAS

被引:73
作者
Carter, G. D. [1 ]
Berry, J. [2 ]
Durazo-Arvizu, R. [2 ]
Gunter, E. [2 ]
Jones, G. [2 ]
Jones, J. [1 ]
Makin, H. L. J. [2 ]
Pattni, P. [1 ]
Sempos, C. T. [2 ,3 ]
Twomey, P. [2 ]
Williams, E. L. [1 ]
Wise, S. A. [3 ]
机构
[1] Charing Cross Hosp, Imperial Coll Healthcare NHS Trust, Clin Biochem Dept, London W6 8RF, England
[2] Charing Cross Hosp, DEQAS Advisory Panel, London W6 8RF, England
[3] NIH, ODS, Bethesda, MD 20892 USA
关键词
Hydroxyvitamin D; Assays; DEQAS; History; Performance; TANDEM MASS-SPECTROMETRY; 25-HYDROXYVITAMIN D-2; CHROMATOGRAPHY;
D O I
10.1016/j.jsbmb.2017.07.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent years have seen a substantial increase in demand for 25-hydroxyvitamin D (25-OHD) assays. DEQAS (the Vitamin D External Quality Assessment Scheme) has been monitoring the performance of these assays since 1989. The first DEQAS distribution was in June 1989 and results were submitted by 13 laboratories in the UK, two of which used HPLC/UV; the rest used ligand binding assays with a tritium tracer. Inter-laboratory CVs (ALTM) ranged from 29.3% (42.7 nmol/L) to 53.7% (20.0 nmol/L). Currently the scheme has participants in 56 countries using 30 methods or variants of methods. In January 2017, 918 participants returned results and inter laboratory CVs (ALTM) ranged from 10.3% (73.1 nmol/L) to 15.3% (29.4 nmol/L). Over the last 27 years, there have been a number of significant milestones in assay development. The first major advance was the development of an iodinated 25-OHD tracer by Hollis and Napoli in 1992, subsequently used in an RIA kit marketed by DiaSorin. This and other commercial radioimmunoassays that followed brought 25-OHD assays within reach of many more non-specialist routine laboratories. With the introduction of fully automated non-isotopic assays without solvent extraction, measurement of 25-OHD became available to any clinical chemistry laboratory with an appropriate analytical platform. However, as the limitations of these non-extraction assays became apparent more laboratories started using LC-MS/MS methodology. Meanwhile the variable accuracy of 25-OHD methods has been addressed by the Vitamin D Standardization Program (VDSP) which encourages manufacturers to produce methods traceable to the reference measurement procedures (RMPs) of NIST, University of Ghent and the Centers for Disease Control and Prevention (CDC). DEQAS changed to an accuracy-based scheme in 2013 and now assesses assay accuracy against the NIST RMP. This review will use DEQAS results and statistics to chart the historical development in 25-OHD assay technology and highlight some of the problems encountered in obtaining reliable results for this most challenging of analytes.
引用
收藏
页码:30 / 35
页数:6
相关论文
共 17 条
  • [1] RAPID ASSAY FOR 25-HYDROXY-VITAMIN-D3 WITHOUT PREPARATIVE CHROMATOGRAPHY
    BELSEY, RE
    DELUCA, HF
    POTTS, JT
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1974, 38 (06) : 1046 - 1051
  • [2] Standardizing Vitamin D Assays: The Way Forward
    Binkley, Neil
    Sempos, Christopher T.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 (08) : 1709 - 1714
  • [3] Automated immunoassays for 25-hydroxyvitamin D (25-OHD): Do plasticisers interfere?
    Carter, G. D.
    Jones, J.
    Ketheeswaran, M.
    Shannon, J.
    Singh, B.
    Kearney, E.
    Berry, J. L.
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2015, 148 : 38 - 40
  • [4] Carter G. D., 1988, J ENDOCRINOL
  • [5] COLDWELL R D, 1987, Steroids, V49, P155, DOI 10.1016/0039-128X(87)90083-3
  • [6] Variability in the analysis of 25-hydroxyvitamin D by liquid chromatography-tandem mass spectrometry: The devil is in the detail
    Couchman, Lewis
    Benton, Christopher M.
    Moniz, Cajetan F.
    [J]. CLINICA CHIMICA ACTA, 2012, 413 (15-16) : 1239 - 1243
  • [7] DORANTES LM, 1978, J LAB CLIN MED, V91, P791
  • [8] Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC:: need for assay-specific decision limits and metabolite-specific assays
    Glendenning, P
    Taranto, M
    Noble, JM
    Musk, AA
    Hammond, C
    Goldswain, PR
    Fraser, WD
    Vasikaran, SD
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2006, 43 : 23 - 30
  • [10] HEALY MJR, 1979, CLIN CHEM, V25, P675